Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock has already tripled this year, on renewed hopes of success for an experimental lupus treatment. Despite this year's big run-up, this clinical-stage biotech stock could still be a gold mine for growth investors.

Aurinia shares probably would have jumped much higher if a safety scare and mixed data for the company's lead candidate weren't weighing on investors' minds. Here's why that pessimism might be overblown.

Image source: Getty Images.

Source: Fool.com